Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John P. Butler MBA | CEO, President & Director | 1.81M | -- | 1964 |
| Dr. Steven Keith Burke M.D. | Senior VP of Research & Development and Chief Medical Officer | 937.39k | -- | 1961 |
| Mr. Erik John Ostrowski M.B.A. | Senior VP, CFO & Chief Business Officer | -- | -- | 1972 |
| Mr. Richard C. Malabre | Chief Accounting Officer | -- | -- | 1961 |
| Ms. Kimberly Garko | Senior VP & Chief Technical Officer | -- | -- | -- |
| Ms. Tracey Vetterick | Vice President of Portfolio Strategy & Corporate Administration | -- | -- | -- |
| Mercedes Carrasco | Senior Director of Investor & Corporate Communications | -- | -- | -- |
| Ms. Carolyn Rucci | Senior VP of Legal, General Counsel & Secretary | -- | -- | -- |
| Ms. Meredith Bowman | Senior VP & Chief People Officer | -- | -- | -- |
| Mr. Nicholas Grund | Senior VP & Chief Commercial Officer | -- | -- | 1970 |
Akebia Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 181
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. Its product pipeline consists of AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. The company has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
May 7, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Akebia Therapeutics, Inc. Earnings Date
Recent Events
September 10, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission